We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Myriad Genetics Acquisition Enhances Capacity to Deliver Companion Diagnostics

By LabMedica International staff writers
Posted on 10 May 2011
Myriad Genetics, Inc. More...
(Salt Lake City, UT, USA) will acquire Rules-Based Medicine (RBM; Austin, TX, USA) for US$80 million in cash. With the new acquisition, Myriad hopes to gain faster entry into the companion diagnostics market.

RBM, with nearly 160 employees, will operate as a wholly owned subsidiary of Myriad under the name Myriad RBM. Some of RBM's employees will be relocated to Utah.

Myriad develops products for predictive, personalized, and prognostic medicine. The bulk of Myriad's revenues comes from its BRAC analysis test, which analyzes a woman's DNA for the BRCA1 and BRCA2 genes, the presence of which greatly increases a woman's chances of inheriting breast and ovarian cancer.

An early pioneer in molecular diagnostics, Myriad's strategy is to understand the role of genes in human disease and use the information to develop and commercialize products that assess a person's risk of developing disease later in life and guide treatment decisions based on an individual's genetic makeup and specific cause of disease

Rules-Based Medicine is a privately owned life sciences company that has well-established relationships with key therapeutic drug companies. It develops molecular diagnostic tests based on novel biomarker patterns. The company recently introduced a multianalyte medical laboratory test for the psychiatric market. RBM also provides information to pharmaceutical and biotech partners to accelerate drug development and improve clinical-trial outcomes

Myriad's purchase of RBM is an example of how companies in the clinical laboratory testing marketplace are preparing to serve the coming demand for companion diagnostic tests.

Related Links:
Myriad Genetics, Inc.
Rules-Based Medicine


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.